FDA approved Veklury (remdesivir) to treat COVID-19. It is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. This drug is given intravenously to hospitalized patients. Remdesivir is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor. Remdesivir is contraindicated in patients with hypersensitivity.
Warnings and Precautions while using Remdesivir
- Elevated transaminase activity, requires monitoring of hepatic function prior to and during use of Veklury;
- Risk of reduced antiviral activity when coadministered with chloroquine phosphate or hydroxychloroquine sulfate;
- Hypersensitivity